Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia
Pennsylvania
19104
United States
Website: http://www.amicusrx.com/
Email: info@amicusrx.com
About Amicus Therapeutics, Inc.
426 articles about Amicus Therapeutics, Inc.
-
Amicus Therapeutics, Inc. to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
1/5/2010
-
Amicus Therapeutics, Inc. Appoints Margaret G. McGlynn, R.Ph.D, to Board of Directors
11/3/2009
-
Amicus Therapeutics, Inc. (JOBS) Reacquires Global Development and Commercialization Rights to Amigal(TM), Plicera(TM) and AT2220 Through a Mutual Termination Agreement with Shire plc (JOBS); Company to Cut 20 Percent Jobs; Announces Third Quarter 2009 Fi
10/30/2009
-
Amicus Therapeutics, Inc. Announces Third Quarter 2009 Financial Results Release Date
10/26/2009
-
Amicus Therapeutics, Inc.' (JOBS) Gaucher Drug Fails in Mid-Stage Trial
10/5/2009
-
Amicus Therapeutics, Inc. Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
9/30/2009
-
Amicus Therapeutics, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
9/10/2009
-
Amicus Therapeutics, Inc. Announces Second Quarter 2009 Financial Results
8/6/2009
-
Amicus Therapeutics, Inc. Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
6/22/2009
-
Amicus Therapeutics, Inc. to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
5/11/2009
-
Amicus Therapeutics, Inc. Announces First Quarter 2009 Financial Results Release Date
5/1/2009
-
Amicus Therapeutics, Inc. to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
3/30/2009
-
Amicus Therapeutics, Inc. Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
3/30/2009
-
Amicus Therapeutics, Inc. Announces Issuance of New Plicera(TM) Composition of Matter Patent
3/25/2009
-
Amicus Therapeutics, Inc. to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
3/11/2009
-
Amicus Therapeutics, Inc. (JOBS) Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
2/27/2009
-
Amicus Therapeutics, Inc. Announces Change to Board of Directors
2/19/2009
-
Amicus Therapeutics, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
2/6/2009
-
Amicus Therapeutics, Inc. Announces Fourth Quarter and Year End 2008 Financial Results Release Date
1/29/2009
-
Amicus Therapeutics, Inc. Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
1/13/2009